AUSTIN, Texas (Reuters) ? Johnson & Johnson said on Thursday it will pay $158 million to settle a Texas lawsuit accusing the drugmaker of improperly marketing its Risperdal anti-psychotic drug to state residents on the Medicaid health program for the poor.
The settlement fully resolves all Risperdal-related claims in Texas, the company said. The agreement is specific to the state of Texas and does not involve any other ongoing state or federal Risperdal litigation.
The deal settles claims brought by Texas in 2004 and involves alleged Medicaid overpayments during the years 1994 to 2008 "and will circumvent potentially lengthy and costly appellate activities," according to a statement from J&J's Janssen Pharmaceuticals unit.
The complaint against J&J and several of its units filed in U.S. district court in Texas had alleged that company representatives "targeted every level of the Texas Medicaid Program with misrepresentations about the safety, superiority, efficacy, appropriate uses and cost effectiveness of Risperdal."
(Reporting by Corrie MacLaggan; additional reporting by Bill Berkrot and Ransdell Pierson in New York; Editing by Michele Gershberg, Lisa Von Ahn and Gunna Dickson)
nhl mph abraham lincoln america got talent 2011 savannah cat rachel maddow apa format
Risperal reproached.
উত্তরমুছুনSame saga here as Eli Lilly Zyprexa.
Johnson and Johnson is a trusted brand we associate with babies.
Risperdal,Zyprexa,as well as the other atypical antipsychotics, are being prescribed for children, even though this is an unapproved, off-label use. An estimated 2.5 million children are now taking atypical antipsychotics. Over half are being given them for Attention Deficit Hyperactivity Disorder,many of these foster children.
Weight gain, increases in triglyceride levels and associated risks for (life-long) diabetes and cardiovascular disease.
--Daniel Haszard
*Tell the truth don't be afraid*